Mariya V. Cherkasova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariya V. Cherkasova has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
19 shared publications - Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
18 shared publications - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
13 shared publications - Fariza A. Cheldieva
V.A. Nasonova Research Institute of Rheumatology
11 shared publications - Kamila S. Nurbaeva
V.A. Nasonova Research Institute of Rheumatology, Moscow 115522, Russia
8 shared publications - Svetlana I. Glukhova
Nasonova Research Institute of Rheumatology
8 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (5) , 533-541
Ovarian reserve and hormonal profile in women with Behçet’s disease
Background . Behçet’s disease (BD) is a chronic systemic vasculitis predominantly manifesting during the reproductive years. Data on the impact of BD on ovarian reserve and hormonal profile in women remain scarce and contradictory. The aim. To assess ovarian reserve and the hormonal profile in women with BD in relation to disease severity and activity. Materials and methods . A cross-sectional study enrolled 44 patients with BD and 32 healthy women aged 18–40 years with regular menstrual cycles. Serum levels of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, estradiol (E2), and total testosterone (T) were measured. Diminished ovarian reserve (DOR) was defined as AMH≤1,1 ng/ml (Bologna/ESHRE (European Society of Human Reproduction and Embryology) criteria). Predictors of DOR were identified using logistic regression; the diagnostic accuracy of hormonal parameters was assessed via ROC analysis. Results . Median AMH levels were comparable between the groups (2.50 vs. 2.45 ng/mL; p=0.64); however, the proportion of patients with DOR was higher in the BD group without reaching statistical significance (27.3% vs. 9.4%; p=0.079). In the multivariate analysis, disease severity was the only independent predictor of DOR (odds ratio (OR) – 2.57; 95 % confidence interval (95% CI): 1.05–6.33; p=0.040). No significant differences in AMH were found across BDCAF (Behçet’s Disease Current Activity Form) activity subgroups (p=0.961). Patients with BD demonstrated significantly lower levels of estradiol (p=0.007) and total testosterone (p=0.009), alongside higher levels of LH (p=0.001), prolactin (pConclusions. Disease severity according to the C.C. Zouboulis et al. classification was the only independent predictor of diminished ovarian reserve. Women with BD demonstrated a characteristic reproductive-endocrine profile: reduced estradiol and total testosterone levels alongside elevated LH, prolactin, and LH/FSH ratio.
- 31 October 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (5) , 533-541
Open AccessOvarian reserve and hormonal profile in women with Behçet’s disease
Background . Behçet’s disease (BD) is a chronic systemic vasculitis predominantly manifesting during the reproductive years. Data on the impact of BD on ovarian reserve and hormonal profile in women remain scarce and contradictory. The aim. To assess ovarian reserve and the hormonal profile in women with BD in relation to disease severity and activity. Materials and methods . A cross-sectional study enrolled 44 patients with BD and 32 healthy women aged 18–40 years with regular menstrual cycles. Serum levels of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, estradiol (E2), and total testosterone (T) were measured. Diminished ovarian reserve (DOR) was defined as AMH≤1,1 ng/ml (Bologna/ESHRE (European Society of Human Reproduction and Embryology) criteria). Predictors of DOR were identified using logistic regression; the diagnostic accuracy of hormonal parameters was assessed via ROC analysis. Results . Median AMH levels were comparable between the groups (2.50 vs. 2.45 ng/mL; p=0.64); however, the proportion of patients with DOR was higher in the BD group without reaching statistical significance (27.3% vs. 9.4%; p=0.079). In the multivariate analysis, disease severity was the only independent predictor of DOR (odds ratio (OR) – 2.57; 95 % confidence interval (95% CI): 1.05–6.33; p=0.040). No significant differences in AMH were found across BDCAF (Behçet’s Disease Current Activity Form) activity subgroups (p=0.961). Patients with BD demonstrated significantly lower levels of estradiol (p=0.007) and total testosterone (p=0.009), alongside higher levels of LH (p=0.001), prolactin (pConclusions. Disease severity according to the C.C. Zouboulis et al. classification was the only independent predictor of diminished ovarian reserve. Women with BD demonstrated a characteristic reproductive-endocrine profile: reduced estradiol and total testosterone levels alongside elevated LH, prolactin, and LH/FSH ratio.
- Open Access
- 22 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2872
Disturbances in Central Sensitization Are Associated with Disease Severity and Alterations in Gene Expression Measured in the Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune rheumatic disease of unknown etiolgy, characterized by erosive polyarthritis that leads to joint destruction and systemic inflammatory lesions in internal organs. Pain is a primary symptom of RA and a major contributor to psychological disturbances, which influence patients’ subjective evaluation of their condition. These psychological issues may stem from disruptions in central pain regulation mechanisms, such as central sensitization (CS), which can also affect central metabolic processes. The objective was to investigate how the severity of central sensitization, measured by the Central Sensitization Inventory (CSI) questionnaire (Part 1), impacts clinical and neuropsychiatric parameters, as well as the expression of genes related to inflammation, tissue destruction, carbohydrate metabolism, and fatty acid metabolism in peripheral blood mononuclear cells (PBMCs) in patients with RA. Methods involved collecting blood samples from 59 RA patients (mean age 52.0 years). Clinical status was assessed using the DAS28 index and serum levels of CRP, ASPA, and RF. Neuropsychiatric parameters were evaluated through questionnaires measuring CS severity score (CSI), pain intensity (VAS, BPI), neuropathic pain (PainDETECT), anxiety and depression (HADS), fatigue (FSS, FACIT-F), fibromyalgia symptoms (FIRST), and pain catastrophizing. Protein expression in PBMCs was measured by ELISA, while gene expression was analyzed using quantitative real-time RT-PCR. All patients exhibited moderate to high disease activity. Participants were divided into four subgroups according to their CSI scores: subclinical (0–29 points), mild (30–39 points), moderate (40–49 points), and severe/extreme (50–100 points). Higher CSI scores correlated with significant increases in neuropsychiatric symptoms and a notable decrease in vitality. However, clinical parameters showed no significant differences among the subgroups. Gene expression analysis revealed upregulation of genes involved in the pentose phosphate pathway (G6PD), antioxidant defense (SOD1), fatty acid metabolism (FASN, CPT1B), apoptosis (CASP3), and tissue destruction and hypernociception (MMP-9) compared to healthy controls. The pro-inflammatory cytokine IL-1β expression was comparable to controls, while TNFα expression was elevated only in patients with severe/extreme CS scores. These findings suggest that CS-related disturbances may contribute to increased disease severity in RA, even in patients receiving active antirheumatic treatment. At the cellular level, disease severity appears linked to dysregulated expression of genes governing central metabolic processes, despite low expression of pro-inflammatory cytokine genes.
- 22 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2872
Open AccessDisturbances in Central Sensitization Are Associated with Disease Severity and Alterations in Gene Expression Measured in the Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune rheumatic disease of unknown etiolgy, characterized by erosive polyarthritis that leads to joint destruction and systemic inflammatory lesions in internal organs. Pain is a primary symptom of RA and a major contributor to psychological disturbances, which influence patients’ subjective evaluation of their condition. These psychological issues may stem from disruptions in central pain regulation mechanisms, such as central sensitization (CS), which can also affect central metabolic processes. The objective was to investigate how the severity of central sensitization, measured by the Central Sensitization Inventory (CSI) questionnaire (Part 1), impacts clinical and neuropsychiatric parameters, as well as the expression of genes related to inflammation, tissue destruction, carbohydrate metabolism, and fatty acid metabolism in peripheral blood mononuclear cells (PBMCs) in patients with RA. Methods involved collecting blood samples from 59 RA patients (mean age 52.0 years). Clinical status was assessed using the DAS28 index and serum levels of CRP, ASPA, and RF. Neuropsychiatric parameters were evaluated through questionnaires measuring CS severity score (CSI), pain intensity (VAS, BPI), neuropathic pain (PainDETECT), anxiety and depression (HADS), fatigue (FSS, FACIT-F), fibromyalgia symptoms (FIRST), and pain catastrophizing. Protein expression in PBMCs was measured by ELISA, while gene expression was analyzed using quantitative real-time RT-PCR. All patients exhibited moderate to high disease activity. Participants were divided into four subgroups according to their CSI scores: subclinical (0–29 points), mild (30–39 points), moderate (40–49 points), and severe/extreme (50–100 points). Higher CSI scores correlated with significant increases in neuropsychiatric symptoms and a notable decrease in vitality. However, clinical parameters showed no significant differences among the subgroups. Gene expression analysis revealed upregulation of genes involved in the pentose phosphate pathway (G6PD), antioxidant defense (SOD1), fatty acid metabolism (FASN, CPT1B), apoptosis (CASP3), and tissue destruction and hypernociception (MMP-9) compared to healthy controls. The pro-inflammatory cytokine IL-1β expression was comparable to controls, while TNFα expression was elevated only in patients with severe/extreme CS scores. These findings suggest that CS-related disturbances may contribute to increased disease severity in RA, even in patients receiving active antirheumatic treatment. At the cellular level, disease severity appears linked to dysregulated expression of genes governing central metabolic processes, despite low expression of pro-inflammatory cytokine genes.
- Open Access
- 31 August 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (4) , 380-385
Glukhova SI. Vaccination of pneumococcal infection in patients with rheumatic diseases (according to the V.A. Nasonova Research Institute of Rheumatology)
Background. Infections of the lower respiratory tract (LRT) and ENT organs in patients with rheumatic diseases (RD) are an urgent problem of rheumatology, the real solution of which can be vaccination. However, there is still insufficient data on the clinical efficacy, immunogenicity, and safety of pneumococcal vaccines in rheumatological patients.The aim – to evaluate the clinical efficacy, immunogenicity, and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with RD who were observed at the V.A. Nasonova Research Institute of Rheumatology.Materials and methods. An open prospective study included 254 patients with RD, including 97 with rheumatoid arthritis (RA), 52 with ankylosing spondylitis (AS), 27 with psoriatic arthritis (PsA), 78 with systemic lupus erythematosus (SLE), including 18 with secondary antiphospholipid syndrome. PPV-23 was administered in a single dose (0.5 ml) intramuscularly. The clinical efficacy of vaccination during the 12-month follow-up period was assessed by the frequency of reported infections of LRT and ENT organs. The level of post-vaccination antibodies (AT) was determined by enzyme immunoassay (ELISA) using a commercial EIA PCP IgG kit (Test Line Clinical Diagnostics, Czech Republic) initially, 1–3 and 12 months after vaccination. The safety of vaccination was determined by the frequency and severity of post-vaccination reactions and the effect on activity and course of RD.Results. The clinical efficacy of PPV-23 during a 12-month follow-up was confirmed in 92.1% of patients with RD. A statistically significant increase in AT levels was detected 1–3 and 12 months after vaccination. 87.5% of patients with RA, 61.5% with AS, 72.7% with PsA, and 56.0% with SLE were “responders” to PPV-23. Post-vaccination local reactions in the vast majority of cases (94.1%) were mild or moderate and stopped on their own. Systemic reactions were rare, mild, and short-term. There was no negative effect of vaccination on the activity of RD, as well as the occurrence of new autoimmune phenomena.Conclusion. The data obtained indicate sufficient clinical efficacy, immunogenicity, and safety of PPV-23 in patients with RD.
- 31 August 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (4) , 380-385
Open AccessGlukhova SI. Vaccination of pneumococcal infection in patients with rheumatic diseases (according to the V.A. Nasonova Research Institute of Rheumatology)
Background. Infections of the lower respiratory tract (LRT) and ENT organs in patients with rheumatic diseases (RD) are an urgent problem of rheumatology, the real solution of which can be vaccination. However, there is still insufficient data on the clinical efficacy, immunogenicity, and safety of pneumococcal vaccines in rheumatological patients.The aim – to evaluate the clinical efficacy, immunogenicity, and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with RD who were observed at the V.A. Nasonova Research Institute of Rheumatology.Materials and methods. An open prospective study included 254 patients with RD, including 97 with rheumatoid arthritis (RA), 52 with ankylosing spondylitis (AS), 27 with psoriatic arthritis (PsA), 78 with systemic lupus erythematosus (SLE), including 18 with secondary antiphospholipid syndrome. PPV-23 was administered in a single dose (0.5 ml) intramuscularly. The clinical efficacy of vaccination during the 12-month follow-up period was assessed by the frequency of reported infections of LRT and ENT organs. The level of post-vaccination antibodies (AT) was determined by enzyme immunoassay (ELISA) using a commercial EIA PCP IgG kit (Test Line Clinical Diagnostics, Czech Republic) initially, 1–3 and 12 months after vaccination. The safety of vaccination was determined by the frequency and severity of post-vaccination reactions and the effect on activity and course of RD.Results. The clinical efficacy of PPV-23 during a 12-month follow-up was confirmed in 92.1% of patients with RD. A statistically significant increase in AT levels was detected 1–3 and 12 months after vaccination. 87.5% of patients with RA, 61.5% with AS, 72.7% with PsA, and 56.0% with SLE were “responders” to PPV-23. Post-vaccination local reactions in the vast majority of cases (94.1%) were mild or moderate and stopped on their own. Systemic reactions were rare, mild, and short-term. There was no negative effect of vaccination on the activity of RD, as well as the occurrence of new autoimmune phenomena.Conclusion. The data obtained indicate sufficient clinical efficacy, immunogenicity, and safety of PPV-23 in patients with RD.
- Open Access
- 4 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 113-119
Use of the AMS questionnaire to hypogonadism screening in men with rheumatoid arthritis
Introduction. The proportion of men with rheumatoid arthritis (RA) reaches 25%. Given the previously identified high frequency of decreased testosterone in men with RA, the issue of clinical diagnosis of hypogonadism is relevant.Aim. To evaluate the effectiveness of the Aging Male Symptoms (AMS) questionnaire for diagnosing hypogonadism among patients with RA.Materials and methods. A cross-sectional continuous study included 78 men with RA who were undergoing inpatient treatment at the V.A. Nasonova Research Institute of Rheumatology. The patients underwent determination of their total testosterone levels. All men completed the AMS questionnaire to screen for clinical signs of testosterone deficiency. A correlation analysis was performed between the AMS scores with the testosterone level and clinical and laboratory parameters of RA. ROC analysis of the sensitivity and specificity of the AMS questionnaire was performed in comparison with laboratory diagnostics of hypogonadism.Results. Based on the results of the questionnaire, androgen deficiency was suspected in 70.5%. Hypogonadism (decreased testosterone levels < 12.0 nmol/l) was detected in 33.3% of patients. A significant negative correlation was found between the total score of the AMS questionnaire and all three subgroups of questions with the level of total testosterone. A moderate correlation was noted between age and the sexual symptoms of the questionnaire. The DAS28 index, the number of swollen joints and the level of C-reactive protein significantly positively correlated with the total score of the AMS, as well as with its somatic and psychological components. When conducting the ROC analysis, the area under the ROC curve was 0.728 (95% CI 0.604–0.851; p < 0.001). The threshold value for the AMS questionnaire at the cut-off point was 38.5 points. The sensitivity and specificity of the model were 75.0% and 69.2%. The diagnostic accuracy of the questionnaire was 51.3%, the positive predictive value was 39.3%, and the negative predictive value was 81.8%.Conclusion. The AMS questionnaire can be effective for diagnosing androgen deficiency symptoms in men with RA, but RA activity makes a significant contribution to the score, which increases the threshold value at which the questionnaire shows satisfactory sensitivity and specificity.
- 4 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 113-119
Open AccessUse of the AMS questionnaire to hypogonadism screening in men with rheumatoid arthritis
Introduction. The proportion of men with rheumatoid arthritis (RA) reaches 25%. Given the previously identified high frequency of decreased testosterone in men with RA, the issue of clinical diagnosis of hypogonadism is relevant.Aim. To evaluate the effectiveness of the Aging Male Symptoms (AMS) questionnaire for diagnosing hypogonadism among patients with RA.Materials and methods. A cross-sectional continuous study included 78 men with RA who were undergoing inpatient treatment at the V.A. Nasonova Research Institute of Rheumatology. The patients underwent determination of their total testosterone levels. All men completed the AMS questionnaire to screen for clinical signs of testosterone deficiency. A correlation analysis was performed between the AMS scores with the testosterone level and clinical and laboratory parameters of RA. ROC analysis of the sensitivity and specificity of the AMS questionnaire was performed in comparison with laboratory diagnostics of hypogonadism.Results. Based on the results of the questionnaire, androgen deficiency was suspected in 70.5%. Hypogonadism (decreased testosterone levels < 12.0 nmol/l) was detected in 33.3% of patients. A significant negative correlation was found between the total score of the AMS questionnaire and all three subgroups of questions with the level of total testosterone. A moderate correlation was noted between age and the sexual symptoms of the questionnaire. The DAS28 index, the number of swollen joints and the level of C-reactive protein significantly positively correlated with the total score of the AMS, as well as with its somatic and psychological components. When conducting the ROC analysis, the area under the ROC curve was 0.728 (95% CI 0.604–0.851; p < 0.001). The threshold value for the AMS questionnaire at the cut-off point was 38.5 points. The sensitivity and specificity of the model were 75.0% and 69.2%. The diagnostic accuracy of the questionnaire was 51.3%, the positive predictive value was 39.3%, and the negative predictive value was 81.8%.Conclusion. The AMS questionnaire can be effective for diagnosing androgen deficiency symptoms in men with RA, but RA activity makes a significant contribution to the score, which increases the threshold value at which the questionnaire shows satisfactory sensitivity and specificity.
- Open Access
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 32-38
Assessment of antiphospholipid antibodies using enzyme-linked immunosorbent assay and chemiluminescent method
Antiphospholipid antibodies (aPL) are a sign of acquired thrombophilia and are associated with recurrent thrombosis and obstetric pathology. According 2006 classification criteria, serological markers of antiphospholipid syndrome (APS) include lupus anticoagulant, moderate and high levels of antibodies to cardiolipin (aСL) and â2-glycoprotein 1 (anti- â2-GP1) IgG and IgM. The task of standardizing aPL values remains unresolved, leading to variability in results.Objective: to evaluate the comparability of IgG/IgM aCL and IgG/IgM anti- â2-GP1 measurement results using enzyme-linked immunosorbent assay (ELISA) and chemiluminescence (CLU) tests.Material and methods. Peripheral blood from 192 patients (147 women and 45 men) was analyzed, 55 patients (29%) had primary APS, 12 (6%) had probable APS, 61 (32%) had systemic lupus erythematosus (SLE) and APS, and 64 (33%) had SLE without APS. IgG/IgM aCL and IgG/IgM anti- â2-GP1 were determined in all participants by ELISA. By CLU method IgG/IgM aCL were analyzed in 192 patients and IgG/IgM anti- â2-GP1 in 191 patients.Results and discussion. The evaluation of the comparability of the results of ELISA and CLU revealed considerable discrepancies in the positive tests. Thus, in 16% of cases, a discrepancy was found in the levels of IgG aCL and IgM aCL by both methods (n=30 and n=31, respectively), in 18% in the level of IgG anti- â2-GP1 (n=34) and in 15% in the level of IgM anti- â2-GP1 (n=28).These discrepancies were to a greater extent associated with a more frequent detection of aPL in CLU when their values were negative in ELISA , indicating the greater information capacity of the CLU method.However, a small number of patients were positive for aPL in ELISA but negative in CLU: 5 with IgG aCL, 4 with IgM aCL, 6 with IgG anti-â2-GP1, and 2 with IgM anti- â2-GP1 .Conclusion. CLU is shown to be a more informative method for determining IgG aCL and IgG anti- â2-GP1 than ELISA (p<0.05).
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 32-38
Open AccessAssessment of antiphospholipid antibodies using enzyme-linked immunosorbent assay and chemiluminescent method
Antiphospholipid antibodies (aPL) are a sign of acquired thrombophilia and are associated with recurrent thrombosis and obstetric pathology. According 2006 classification criteria, serological markers of antiphospholipid syndrome (APS) include lupus anticoagulant, moderate and high levels of antibodies to cardiolipin (aСL) and â2-glycoprotein 1 (anti- â2-GP1) IgG and IgM. The task of standardizing aPL values remains unresolved, leading to variability in results.Objective: to evaluate the comparability of IgG/IgM aCL and IgG/IgM anti- â2-GP1 measurement results using enzyme-linked immunosorbent assay (ELISA) and chemiluminescence (CLU) tests.Material and methods. Peripheral blood from 192 patients (147 women and 45 men) was analyzed, 55 patients (29%) had primary APS, 12 (6%) had probable APS, 61 (32%) had systemic lupus erythematosus (SLE) and APS, and 64 (33%) had SLE without APS. IgG/IgM aCL and IgG/IgM anti- â2-GP1 were determined in all participants by ELISA. By CLU method IgG/IgM aCL were analyzed in 192 patients and IgG/IgM anti- â2-GP1 in 191 patients.Results and discussion. The evaluation of the comparability of the results of ELISA and CLU revealed considerable discrepancies in the positive tests. Thus, in 16% of cases, a discrepancy was found in the levels of IgG aCL and IgM aCL by both methods (n=30 and n=31, respectively), in 18% in the level of IgG anti- â2-GP1 (n=34) and in 15% in the level of IgM anti- â2-GP1 (n=28).These discrepancies were to a greater extent associated with a more frequent detection of aPL in CLU when their values were negative in ELISA , indicating the greater information capacity of the CLU method.However, a small number of patients were positive for aPL in ELISA but negative in CLU: 5 with IgG aCL, 4 with IgM aCL, 6 with IgG anti-â2-GP1, and 2 with IgM anti- â2-GP1 .Conclusion. CLU is shown to be a more informative method for determining IgG aCL and IgG anti- â2-GP1 than ELISA (p<0.05).
- Open Access
- 27 December 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (6) , 627-632
Clinical and instrumental characteristics of psoriatic arthritis in men depending on testosterone levels
The aim – to study the incidence of hypogonadism in men with psoriatic arthritis (PsA) and to assess its impact on PsA and comorbidities.Materials and methods. A cross-sectional continuous study included 128 men with PsA who were hospitalized at the V.A. Nasonova Research Institute of Rheumatology. The patients underwent determination of their total testosterone levels and subsequent division into subgroups with normal (≥12.0 nmol/l) and reduced levels. An intergroup comparison was conducted for the main indicators used in clinical rheumatology practice to assess the stage, activity, and other medical and demographic characteristics of PsA, as well as for comorbidities. A correlation analysis was performed between the level of total testosterone and some clinical and laboratory parameters.Results. The incidence of reduced total testosterone levels was 36.7%. Patients with testosterone deficiency were older (47.9±10.3 vs 40.1±12.1 years; ppp=0.001). They had higher mean glucose levels (5.9±1.39 vs 5.34±0.57 mmol/l; p=0.001) and frequency of impaired fasting glycemia with similar frequency of type 2 diabetes mellitus. Patients with hypogonadism were characterized by higher uric acid levels (402.9±99.3 vs 354.0±81.5 μmol/L; p=0.003) and the frequency of hyperuricemia. A lower proportion of HLA-B27 positive patients was noted in the hypogonadism group, as well as a more frequent occurrence of stage III sacroiliitis (p=0.004) and a smaller amplitude of lateral flexion in the spine (10.3±3.3 vs 12.4±4.3 cm; p=0.014). Significant negative relationships were found between total testosterone levels and age, body mass index, glucose and uric acid levels, as well as a positive relationship with the amplitude of lateral flexion and chest excursion.Conclusion. Hypogonadism was detected in one third of patients with PsA. Decreased testosterone levels were observed in older individuals and were associated with metabolic disorders, as well as with decreased spinal mobility and the presence of stage III of sacroiliitis.
- 27 December 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (6) , 627-632
Open AccessClinical and instrumental characteristics of psoriatic arthritis in men depending on testosterone levels
The aim – to study the incidence of hypogonadism in men with psoriatic arthritis (PsA) and to assess its impact on PsA and comorbidities.Materials and methods. A cross-sectional continuous study included 128 men with PsA who were hospitalized at the V.A. Nasonova Research Institute of Rheumatology. The patients underwent determination of their total testosterone levels and subsequent division into subgroups with normal (≥12.0 nmol/l) and reduced levels. An intergroup comparison was conducted for the main indicators used in clinical rheumatology practice to assess the stage, activity, and other medical and demographic characteristics of PsA, as well as for comorbidities. A correlation analysis was performed between the level of total testosterone and some clinical and laboratory parameters.Results. The incidence of reduced total testosterone levels was 36.7%. Patients with testosterone deficiency were older (47.9±10.3 vs 40.1±12.1 years; ppp=0.001). They had higher mean glucose levels (5.9±1.39 vs 5.34±0.57 mmol/l; p=0.001) and frequency of impaired fasting glycemia with similar frequency of type 2 diabetes mellitus. Patients with hypogonadism were characterized by higher uric acid levels (402.9±99.3 vs 354.0±81.5 μmol/L; p=0.003) and the frequency of hyperuricemia. A lower proportion of HLA-B27 positive patients was noted in the hypogonadism group, as well as a more frequent occurrence of stage III sacroiliitis (p=0.004) and a smaller amplitude of lateral flexion in the spine (10.3±3.3 vs 12.4±4.3 cm; p=0.014). Significant negative relationships were found between total testosterone levels and age, body mass index, glucose and uric acid levels, as well as a positive relationship with the amplitude of lateral flexion and chest excursion.Conclusion. Hypogonadism was detected in one third of patients with PsA. Decreased testosterone levels were observed in older individuals and were associated with metabolic disorders, as well as with decreased spinal mobility and the presence of stage III of sacroiliitis.
- Open Access
- 13 December 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (6) , 46-52
Results of a three-year observation of the course of non-radiological axial spondyloarthritis
Identification of the non-radiological stage of axial spondyloarthritis (nr-axSpA) has contributed to the improvement of diagnostics and the expansion of therapeutic approaches in the early stages of the disease. However, there is still an unmet need for effective treatment of patients with active nr-axSpA.Objective: to evaluate the dynamics of nr-axSpA in patients in the Kaliningrad region and to identify additional factors influencing the radiological progression of the disease.Material and methods. A total of 68 patients with nr-axSpA were examined at baseline and during 3 year follow-up, most of them were women (62%). The median age of the participants was 27.5 [23.0; 33.3] years. The duration of diagnosis was 1 [1; 2] years. HLA-B27 antigen positivity was present in 40% of cases. Patients at baseline and during follow-up underwent a standard clinical and laboratory examination, pelvic radiography and magnetic resonance imaging of the sacroiliac joints. In addition, cytokine levels (visfatin, PPM1A, MIF, serum calprotectin) and the concentration of IgCD74 antibodies were determined.Results and discussion. After 3 years of follow-up, the diagnosis still met the criteria for nr-axSpA in 30 (44.1%) of the 68 patients, in 16 (23.5%) it transformed into radiographic axSpA (r-axSpA), in 7 (10.3%) – to axial psoriatic arthritis, in 13 (19.1%) the clinical picture no longer met the criteria for nr-axSpA, 2 (3%) patients dropped out of the study. When analyzing the values of visfatin, PPM1A, MIF and serum calprotectin, no differences were found between nr-axSpA and r-axSpA, while the average concentrations of IgCD74 antibodies were slightly higher in patients with nr-axSpA (7.4 and 5.0 ng/ml respectively). It was shown that the probability of radiological progression from nr-axSpA to r-axSpA increased 3.308-fold with a one-unit increase in the ASDAS (Ankylosing Spondylitis Disease Activity Score) index.Conclusion. The median duration of nr-axSpA diagnostics in the Kaliningrad region was 1 year. In terms of dynamics, after 3 years of observation, 44.1% of patients still met the criteria for nr-axSpA, and radiological progression to r-axSpA was observed in 23.5% of cases. High values of the ASDAS index and its increase by 1 unit increased the speed of radiological progression of nr-axSpA by 3.308 times. The difficulties in the early diagnosis of axSpA in practice necessitate the establishment of reference centers to obtain expert opinions on issues of differential diagnosis and treatment choices in patients with nr-axSpA and ankylosing spondylitis.
- 13 December 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (6) , 46-52
Open AccessResults of a three-year observation of the course of non-radiological axial spondyloarthritis
Identification of the non-radiological stage of axial spondyloarthritis (nr-axSpA) has contributed to the improvement of diagnostics and the expansion of therapeutic approaches in the early stages of the disease. However, there is still an unmet need for effective treatment of patients with active nr-axSpA.Objective: to evaluate the dynamics of nr-axSpA in patients in the Kaliningrad region and to identify additional factors influencing the radiological progression of the disease.Material and methods. A total of 68 patients with nr-axSpA were examined at baseline and during 3 year follow-up, most of them were women (62%). The median age of the participants was 27.5 [23.0; 33.3] years. The duration of diagnosis was 1 [1; 2] years. HLA-B27 antigen positivity was present in 40% of cases. Patients at baseline and during follow-up underwent a standard clinical and laboratory examination, pelvic radiography and magnetic resonance imaging of the sacroiliac joints. In addition, cytokine levels (visfatin, PPM1A, MIF, serum calprotectin) and the concentration of IgCD74 antibodies were determined.Results and discussion. After 3 years of follow-up, the diagnosis still met the criteria for nr-axSpA in 30 (44.1%) of the 68 patients, in 16 (23.5%) it transformed into radiographic axSpA (r-axSpA), in 7 (10.3%) – to axial psoriatic arthritis, in 13 (19.1%) the clinical picture no longer met the criteria for nr-axSpA, 2 (3%) patients dropped out of the study. When analyzing the values of visfatin, PPM1A, MIF and serum calprotectin, no differences were found between nr-axSpA and r-axSpA, while the average concentrations of IgCD74 antibodies were slightly higher in patients with nr-axSpA (7.4 and 5.0 ng/ml respectively). It was shown that the probability of radiological progression from nr-axSpA to r-axSpA increased 3.308-fold with a one-unit increase in the ASDAS (Ankylosing Spondylitis Disease Activity Score) index.Conclusion. The median duration of nr-axSpA diagnostics in the Kaliningrad region was 1 year. In terms of dynamics, after 3 years of observation, 44.1% of patients still met the criteria for nr-axSpA, and radiological progression to r-axSpA was observed in 23.5% of cases. High values of the ASDAS index and its increase by 1 unit increased the speed of radiological progression of nr-axSpA by 3.308 times. The difficulties in the early diagnosis of axSpA in practice necessitate the establishment of reference centers to obtain expert opinions on issues of differential diagnosis and treatment choices in patients with nr-axSpA and ankylosing spondylitis.
- Open Access
- 13 December 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (6) , 61-66
Serum calprotectin in Behcet's disease
Objective: to assess the level of serum calprotectin (CLP) in Behcet's disease (BD).Material and methods. The study included 90 patients with BD (35 women and 55 men) and 30 healthy controls (22 women and 8 men). The mean age of the BD patients was 32 [26; 37] years, that of the control subjects was 30 [25; 37] years. Serum CLP levels were measured with an enzyme immunoassay using a reagent kit from Bulhmann Laboratories AG (Switzerland). Results and discussion. CLP levels were statistically significantly higher in patients with BD compared to healthy controls (median 4.08 [2.81; 7.25] vs. 2.86 [2.15; 3.92] μg/ml; p=0.003). Elevated serum CLP levels were found in 23 (26%) of the 90 patients with BD. Patients with high CLP levels were more likely to have active uveitis (odds ratio, OR 4.741; p=0.011), pustulosis (OR 3.41; p=0.044), arthritis (OR 13.89; p=0.014) and high BD activity (OR 3.195; p=0.029). A direct correlation was found between CLP level and BDCAF activity index (rs=0.415, pConclusion. Serum CLP levels are elevated in patients with BD and are associated with high disease activity, active uveitis, pustulosis and arthritis.
- 13 December 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (6) , 61-66
Open AccessSerum calprotectin in Behcet's disease
Objective: to assess the level of serum calprotectin (CLP) in Behcet's disease (BD).Material and methods. The study included 90 patients with BD (35 women and 55 men) and 30 healthy controls (22 women and 8 men). The mean age of the BD patients was 32 [26; 37] years, that of the control subjects was 30 [25; 37] years. Serum CLP levels were measured with an enzyme immunoassay using a reagent kit from Bulhmann Laboratories AG (Switzerland). Results and discussion. CLP levels were statistically significantly higher in patients with BD compared to healthy controls (median 4.08 [2.81; 7.25] vs. 2.86 [2.15; 3.92] μg/ml; p=0.003). Elevated serum CLP levels were found in 23 (26%) of the 90 patients with BD. Patients with high CLP levels were more likely to have active uveitis (odds ratio, OR 4.741; p=0.011), pustulosis (OR 3.41; p=0.044), arthritis (OR 13.89; p=0.014) and high BD activity (OR 3.195; p=0.029). A direct correlation was found between CLP level and BDCAF activity index (rs=0.415, pConclusion. Serum CLP levels are elevated in patients with BD and are associated with high disease activity, active uveitis, pustulosis and arthritis.
- Open Access
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 408–417
Thrombotic antiphospholipid syndrome: Recurrent thromboses
Thrombotic antiphospholipid syndrome (APS) is a condition affecting young people in whom a thromboembolic event occurs in the presence of circulating antiphospholipid antibodies (aPL).The aim of this study was the evaluation of the incidence of recurrent thrombosis and its risk factors in antiphospholipid syndrome.Material and methods. The retrospective study included 98 patients with aPL who were followed up at the institute from 2014 to 2023, of whom 66 (67%) were women and 32 (33%) were men. Of the 98 patients with aPL, 48 (49%) had a diagnosis of systemic lupus erythematosus (SLE). Antiphospholipid antibodies (aPL), including antibodies to cardiolipin (IgG/IgM aCL), antibodies to ß2-glycoprotein 1 (IgG/IgM aß2GP1), antibodies to ß2-glycoprotein IgG against domain 1 (IgG aß2GP1-D1), antibodies to phosphatidylserine/prothrombin complex (IgG/ IgM aPS/PT) and other thrombotic risk factors. aPL was assessed by enzyme-linked immunosorbent assay (ELISA) and chemoluminescence assay (CHLA).Results. Thrombosis recurrence was reported in 62 (63%) of 98 patients, and 36 (35%) did not. The main cause of recurrent thrombosis was treatment with direct oral anticoagulants (DOACs). 24 (38.7%) of 62 patients with recurrent thrombosis were treated with DOACs, the duration of which ranged from 6 to 24 months. The next most common cause of recurrent thrombosis was the lack of continuous anticoagulant therapy in 20 (32.5%) of the patients. In 17 (27.4%) of the patients, the recurrence occurred while they were still taking warfarin. In 10 (41.7%) of the 24 patients, the recurrent thrombosis was arterial in origin. This was associated with recurrent cerebral circulation problems. The level of positivity did not matter, but all had triple IgG aPL positivity. 5 had lupus anticoagulant (LA) at the onset of the disease before anticoagulant use. IgG aPS/PT was most important in association with recurring thrombosis in the ELISA: 45 (72.6%) of 62 patients with recurring thrombosis were positive for IgG aPS/PT, compared with 19 (52.8%) of 36 patients without recurring thrombosis. The detection of all aPL was more frequent in CHMA than in ELISA. However, the definition of aPL in ELISA is recommended according to the latest classification criteria. Triple IgG positivity for aCL of IgG aß2GP1, IgG aß2GP1-D1 and CHMA remained a risk factor for recurrent thrombosis and increased the risk of recurrence more than threefold. Obesity was a risk factor for recurrent thrombosis, with a 5-fold increased risk of recurrent thrombosis in obese compared to non-obese patients (p=0.01).Conclusions. Recurrent thrombosis in APS is largely associated with IgG aCL, IgG aß2GP1, IgG aß2GP1-D1, IgG aPS/PT. Triple IgG aPL positivity in any combination significantly increased recurrent thrombosis risk.The presence of any type of aPL IgG in both ELISA and CHLA influenced the recurrence rate of thrombosis in APS.Obesity was a significant risk factor for recurrent thrombosis.
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 408–417
Open AccessThrombotic antiphospholipid syndrome: Recurrent thromboses
Thrombotic antiphospholipid syndrome (APS) is a condition affecting young people in whom a thromboembolic event occurs in the presence of circulating antiphospholipid antibodies (aPL).The aim of this study was the evaluation of the incidence of recurrent thrombosis and its risk factors in antiphospholipid syndrome.Material and methods. The retrospective study included 98 patients with aPL who were followed up at the institute from 2014 to 2023, of whom 66 (67%) were women and 32 (33%) were men. Of the 98 patients with aPL, 48 (49%) had a diagnosis of systemic lupus erythematosus (SLE). Antiphospholipid antibodies (aPL), including antibodies to cardiolipin (IgG/IgM aCL), antibodies to ß2-glycoprotein 1 (IgG/IgM aß2GP1), antibodies to ß2-glycoprotein IgG against domain 1 (IgG aß2GP1-D1), antibodies to phosphatidylserine/prothrombin complex (IgG/ IgM aPS/PT) and other thrombotic risk factors. aPL was assessed by enzyme-linked immunosorbent assay (ELISA) and chemoluminescence assay (CHLA).Results. Thrombosis recurrence was reported in 62 (63%) of 98 patients, and 36 (35%) did not. The main cause of recurrent thrombosis was treatment with direct oral anticoagulants (DOACs). 24 (38.7%) of 62 patients with recurrent thrombosis were treated with DOACs, the duration of which ranged from 6 to 24 months. The next most common cause of recurrent thrombosis was the lack of continuous anticoagulant therapy in 20 (32.5%) of the patients. In 17 (27.4%) of the patients, the recurrence occurred while they were still taking warfarin. In 10 (41.7%) of the 24 patients, the recurrent thrombosis was arterial in origin. This was associated with recurrent cerebral circulation problems. The level of positivity did not matter, but all had triple IgG aPL positivity. 5 had lupus anticoagulant (LA) at the onset of the disease before anticoagulant use. IgG aPS/PT was most important in association with recurring thrombosis in the ELISA: 45 (72.6%) of 62 patients with recurring thrombosis were positive for IgG aPS/PT, compared with 19 (52.8%) of 36 patients without recurring thrombosis. The detection of all aPL was more frequent in CHMA than in ELISA. However, the definition of aPL in ELISA is recommended according to the latest classification criteria. Triple IgG positivity for aCL of IgG aß2GP1, IgG aß2GP1-D1 and CHMA remained a risk factor for recurrent thrombosis and increased the risk of recurrence more than threefold. Obesity was a risk factor for recurrent thrombosis, with a 5-fold increased risk of recurrent thrombosis in obese compared to non-obese patients (p=0.01).Conclusions. Recurrent thrombosis in APS is largely associated with IgG aCL, IgG aß2GP1, IgG aß2GP1-D1, IgG aPS/PT. Triple IgG aPL positivity in any combination significantly increased recurrent thrombosis risk.The presence of any type of aPL IgG in both ELISA and CHLA influenced the recurrence rate of thrombosis in APS.Obesity was a significant risk factor for recurrent thrombosis.